Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $19.0 million.

  • aTYR PHARMA's Change in Acquisitions & Divestments fell 896.02% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.1 million, marking a year-over-year decrease of 1570.28%. This contributed to the annual value of $86.4 million for FY2024, which is 511.37% down from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Change in Acquisitions & Divestments is $19.0 million, which was down 896.02% from $21.5 million recorded in Q2 2025.
  • aTYR PHARMA's Change in Acquisitions & Divestments' 5-year high stood at $33.6 million during Q3 2023, with a 5-year trough of $2.3 million in Q1 2021.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $20.0 million (2024), whereas its average is $19.1 million.
  • In the last 5 years, aTYR PHARMA's Change in Acquisitions & Divestments crashed by 8430.03% in 2021 and then soared by 53043.48% in 2022.
  • Quarter analysis of 5 years shows aTYR PHARMA's Change in Acquisitions & Divestments stood at $8.3 million in 2021, then soared by 238.09% to $28.1 million in 2022, then dropped by 2.18% to $27.5 million in 2023, then decreased by 27.27% to $20.0 million in 2024, then fell by 5.0% to $19.0 million in 2025.
  • Its Change in Acquisitions & Divestments was $19.0 million in Q3 2025, compared to $21.5 million in Q2 2025 and $18.7 million in Q1 2025.